Susquehanna International Group, LLP Akebia Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$0.94 - $1.55 $47,094 - $77,655	-50,100 Reduced 31.65%	108,200 $142,000
Q2 2024 Aug 15, 2024	SELL	$0.86 - $1.63 $33,884 - $64,221	-39,400 Reduced 19.93%	158,300 $161,000
Q1 2024 May 07, 2024	SELL	$1.27 - $2.24 $18,161 - $32,032	-14,300 Reduced 6.75%	197,700 $361,000
Q4 2023 Feb 14, 2024	BUY	$0.8 - $1.28 $61,120 - $97,792	76,400 Added 56.34%	212,000 $262,000
Q3 2023 Nov 14, 2023	BUY	$0.87 - $1.84 $65,511 - $138,552	75,300 Added 124.88%	135,600 $154,000
Q2 2023 Aug 11, 2023	BUY	$0.51 - $1.43 $1,887 - $5,291	3,700 Added 6.54%	60,300 $55,000
Q1 2023 May 16, 2023	BUY	$0.56 - $1.15 $19,656 - $40,365	35,100 Added 163.26%	56,600 $31,000
Q4 2022 Feb 14, 2023	SELL	$0.25 - $0.58 $10,250 - $23,780	-41,000 Reduced 65.6%	21,500 $12,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $10,800 - $16,560	-36,000 Reduced 36.55%	62,500 $20,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $346M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.